← All trials
NCT05482828
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2010
- Primary completion
- Dec 31, 2011
- Completion date
- —
- First posted
- Aug 1, 2022
- Last posted
- Aug 1, 2022
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Korea Health Industry Development InstituteLead sponsor
- Korea Health Industry Development InstituteReponsible party - principal investigator
- Daejeon UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.